



## **Alpha Cancer Technologies Inc. Announces Presentation of ACT-101 study results in pre-clinical model of Myasthenia Gravis (MG) at the 13th International Conference on Myasthenia Gravis and Related Disorders**

Toronto, Canada May 15, 2017 -- Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with autoimmune diseases and cancer based on its proprietary recombinant human Alpha Fetoprotein today announced that an abstract highlighting the results of a study of ACT-101 (recombinant human alpha fetoprotein or AFP) in the treatment of myasthenia gravis has been presented at the 13th International Conference on Myasthenia Gravis and Related Disorders held on May 15-17, 2017 in New York. This conference was organized by the Myasthenia Gravis Foundation of America and the New York Academy of Sciences. The study was presented by the principal investigator, by Dr. Linda Kusner of the Laboratory for Myasthenia Gravis Research at George Washington University School of Medicine & Health Sciences.

The study in a classical animal model of experimental autoimmune MG (EAMG) showed clear evidence of efficacy of ACT-101 in reducing clinical score of disease activity and increasing muscle strength in treated animals. The study also suggested that ACT-101 can significantly reduce the complement cascade that has been shown to play an integral role in causing clinical symptoms of acetylcholine receptor antibodies driven MG. Furthermore, as expected, no safety issues were observed in the study. "These results provide strong support to our continuing efforts in developing ACT-101 as a safe and effective treatment for the difficult to manage symptoms of MG." said Igor Sherman Ph.D., CEO of ACT.

One of the leading experts and author of numerous publications in the field of MG, Dr. Oded Abramsky, Head of Neuroimmunology Unit at Hadassah Medical Centre in Israel commented "I am confident that ACT-101 will become an effective therapy for treating several autoimmune diseases without toxic side effects which will give it significant advantage over existing therapies."

The poster presentation details are as follows:

**Title: "PRECLINICAL PILOT STUDY OF ALPHA-FETOPROTEIN ON MODERATION OF MG WEAKNESS"**

**Poster Session:** Poster Session at Marriott Downtown, 85 West St., New York, NY 10280

**Session Date/Time:** May 15, 2017 from 6:00 to 8:30 PM

**Authors:** Linda L. Kusner PhD, Manjitha Sengupta PhD, Gabriela Aguilo-Seara, Igor Sherman PhD

###

### **About Alpha Cancer Technologies Inc.**

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in auto-immune and oncology disease indications. The company's drug products use proprietary recombinant human alpha fetoprotein (ACT-101 or AFP) to directly impact auto-immune diseases (myasthenia gravis, Inflammatory Bowel Disease (Crohn's/Colitis), Hashimoto disease) and uses AFP to carry chemotherapy agents (ACT-901, 902, 903) targeted directly to AFP receptors found on most cancer cells.

ACT-101 has received Orphan Drug Designation for the treatment of myasthenia gravis from the U.S. Food and Drug Administration (FDA).

ACT has exclusive worldwide rights to its proprietary recombinant human AFP with over \$100 million spent on the development of the in-licensed technology. Clinical studies of ACT-101 have demonstrated safety in over 300 patients and established a robust Drug Master file with the FDA including manufacturing, toxicology, and human safety.



## **About Myasthenia Gravis**

Autoimmune myasthenia gravis (MG) is the most common primary disorder of neuromuscular transmission and is a disorder of the neuromuscular junction caused in the majority of patients by autoantibodies directed against the postsynaptic nicotinic acetylcholine receptor (AChR). Acetylcholine receptor (AChR) antibodies are detected in the serum of more than 80% of patients with generalized myasthenia gravis. The prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population and women are more often affected than men. The classic clinical presentation of MG has been well characterized as fluctuating muscle weakness affecting particular muscle groups. The course of disease is variable but usually progressive. Cholinesterase inhibitors, corticosteroids and immunosuppressants are commonly used classes of drugs to treat MG patients but these drugs do not prevent disease progression and are associated with serious side effects.

## **Forward-Looking Statements**

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities legislation (collectively, the "forward-looking statements"). These forward-looking statements relate to, among other things, ACT's objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management.

Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to, the availability of capital, changes in capital markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, unproven markets for technologies in development, the cost and supply of raw materials, management of growth, effects of payers' willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.

[www.alpha-cancer.com](http://www.alpha-cancer.com)

### **For more information, please contact:**

Richard Potts, Chairman

**Alpha Cancer Technologies Inc.**

Tel: +1 (416) 464-2678

Email: [richard@alpha-cancer.com](mailto:richard@alpha-cancer.com)

Vasilios Kofitsas, Senior Director

**Back Bay Life Science Advisors**

Tel: +1(617) 933-5821

[vkofitsas@bblsa.com](mailto:vkofitsas@bblsa.com)